Glutathione and N-acetylcysteine conjugates of α-methyldopamine produce serotonergic neurotoxicity:: Possible role in methylenedioxyamphetamine-mediated neurotoxicity

被引:99
作者
Bai, FJ [1 ]
Lau, SS [1 ]
Monks, TJ [1 ]
机构
[1] Univ Texas, Coll Pharm, Div Pharmacol & Toxicol, Austin, TX 78712 USA
关键词
D O I
10.1021/tx990084t
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Direct injection of either 3,4-(+/-)-methylenedioxymethamphetamine (MDMA) or 3,4-(+/-)methylenedioxyamphetamine (MDA) into the brain fails to reproduce the serotonergic neurotoxicity seen following peripheral administration. The serotonergic neurotoxicity of MDA and MDMA therefore appears to be dependent upon the generation of a neurotoxic metabolite, or metabolites, the identity of which remains unclear. alpha-Methyldopamine (alpha-MeDA) is a major metabolite of both MDA and MDMA. We have shown that intracerebroventricular (icv) injection of 2,5-bis(glutathion-S-yl)-alpha-methyldopamine [2,5-bis(glutathion-S-yl)-alpha-MeDA] causes decreases in serotonin concentrations in the striatum, cortex, and hippocampus, and neurobehavioral effects similar to those seen following MDA and MDMA administration. In contrast, although 5-(glutathion-S-yl)-alpha-methyldopamine [5-(glutathion-S-yl)-alpha-MeDA] and 5-(N-acetylcystein-S-yl)-alpha-methyldopamine [5-(N-acetylcysteinS-yl)-alpha-MeDA] produce neurobehavioral changes similar to those seen with MDA and MDMA, and acute changes in brain 5-HT and dopamine concentrations, neither conjugate caused long-term. decreases in 5-HT concentrations. We now report that direct intrastriatal or intracortical administration of 5-(glutathion-S-yl) alpha-MeDA (4 x 200 or 4 x 400 nmol), 5-(N-acetylcystein-S-yl)-alpha-MeDA (4 x 7 or 4 x 20 nmol), and 2,5-bis(glutathion-S-yl)-alpha-MeDA (4 x 150 or 4 x 300 nmol) causes significant decreases in striatal and cortical 5-HT concentrations (7 days following the last injection). Interestingly, intrastriatal injection of 5-(glutatkion-S-yl)-alpha-MeDA or 2,5-bis(glutathion-S-yl)-alpha-MeDA, but not 5-(N-acetylcystein-S-yl)-alpha-methyldopamin, also caused decreases in 5-HT concentrations in the ipsilateral cortex. The same pattern of changes was seen when the conjugates were injected into the cortex. The effects of the thioether conjugates of alpha-MeDA were confined to 5-HT nerve terminal fields, since no significant changes in monoamine neurotransmitter levels were detected in brain regions enriched with 5-HT cell bodies (midbrain/diencephalon/ telencephalon and pons/medulla). In addition, the effects of the conjugates were selective with respect to the serotonergic system, as no significant changes were seen in dopamine or norepinephrine concentrations. The results indicate that thioether conjugates of alpha-MeDA are selective serotonergic neurotoxicants. Nonetheless, a role for these conjugates in the toxicity observed following systemic administration of MDA and MDMA. remains to be demonstrated, and requires further experimentation.
引用
收藏
页码:1150 / 1157
页数:8
相关论文
共 50 条
  • [1] [Anonymous], [No title captured]
  • [2] Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes
    Baez, S
    SeguraAguilar, J
    Widersten, M
    Johansson, AS
    Mannervik, B
    [J]. BIOCHEMICAL JOURNAL, 1997, 324 : 25 - 28
  • [3] BATTAGLIA G, 1987, J PHARMACOL EXP THER, V242, P911
  • [4] SUPEROXIDE RADICALS MEDIATE THE BIOCHEMICAL EFFECTS OF METHYLENEDIOXYMETHAMPHETAMINE (MDMA) - EVIDENCE FROM USING CUZN-SUPEROXIDE DISMUTASE TRANSGENIC MICE
    CADET, JL
    LADENHEIM, B
    HIRATA, H
    ROTHMAN, RB
    ALI, S
    CARLSON, E
    EPSTEIN, C
    MORAN, TH
    [J]. SYNAPSE, 1995, 21 (02) : 169 - 176
  • [5] COMMINS DL, 1987, J PHARMACOL EXP THER, V241, P338
  • [6] Cuomo M J, 1994, J Am Coll Health, V42, P271
  • [7] GOLLAMUDI R, 1989, NEUROTOXICOLOGY, V10, P455
  • [8] TOXICITY AND DEATHS FROM 3,4-METHYLENEDIOXYMETHAMPHETAMINE (ECSTASY)
    HENRY, JA
    JEFFREYS, KJ
    DAWLING, S
    [J]. LANCET, 1992, 340 (8816) : 384 - 387
  • [9] HIRAMATSU M, 1990, J PHARMACOL EXP THER, V254, P521
  • [10] JOHNSON LD, 1997, NATL SURVEY RESULTS, V2